MG-132

Catalog No.S2619

MG-132 Chemical Structure

Molecular Weight(MW): 475.62

MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.

Size Price Stock Quantity  
USD 50 In stock
USD 170 In stock
USD 470 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Selleck's MG-132 had a noticeably greater effect when compared with similar products from Sigma: This is directly due to using the (S, R, S) - (-) - 2 configuration.

P21 protein can be degraded through ubiquitylation pathway. Inhibition of proteasome activities results in the accumulation of P21 protein, therefore, the more powerful the inhibiting effect, the more P21 protein is accumulated. (testing protein: P21; Cell line: Hela; treatment condition: final concentration of MG-132 is 5μM, with a 6 hour treatment time)

Cited by 180 Publications

Purity & Quality Control

Choose Selective Proteasome Inhibitors

Biological Activity

Description MG132 is a potent cell-permeable proteasome and calpain inhibitor with IC50s of 0.1 and 1.2 μM for the inhibition of proteasome and calpain, respectively.
Targets
Proteasome [9]
(Cell-free assay)
100 nM
In vitro

MG-132 displays >1000 times more activity than ZLLal in inhibiting the ZLLL-MCA-degrading activity of 20S proteasome with IC50 of 100 nM versus 110 μM. MG-132 also inhibits calpain with IC50 of 1.2 μM. MG-132 induces neurite outgrowth in PC12 cells at an optimal concentration of 20 nM, displaying 500 times more potency than ZLLal. [1] MG-132 (10 μM) potently inhibits TNF-α-induced NF-κB activation, interleukin-8 (IL-8) gene transcription, and IL-8 protein release in A549 cells by inhibition of proteasome-mediated IκBα degradation. [2] MG-132 treatment potently induces p53-dependent apoptosis in KIM-2 cells by 26S proteasome inhibition. [3] Unlike BzLLLCOCHO or PS-341, MG-132 treatment results in weak inhibition of the chymotrypsinlike (CT-L) and peptidylglutamyl peptide hydrolysing (PGPH) activities of the 26S proteasome, whereas multiple myeloma cells (U266 and OPM-2) are more sensitive to induction of apoptosis by MG-132 than BzLLLCOCHO. [4] MG-132 (1 μM) sensitizes TRAIL-resistant prostate cancer cells by activating the AP-1 family members c-Fos and c-Jun, which, in turn, repress the antiapoptotic molecule c-FLIP(L). [5] MG-132 significantly enhances the ability of inositol hexakisphosphate (IP6) to reduce cellular metabolic activity in both PC3 and DU145 androgen-independent prostate cancer (AIPCa) cell lines. [6]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LPS-stimulated RAW264.7 cells NH3l[2ZHfW6ldHnvckBCe3OjeR?= NHTjbnozPSEQvF2= NGHpNmJFVVOR NEWy[JlKdmirYnn0d{BvcXS{aXOgc5hq\GVicILv[JVkfGmxbjD3bZRpKEmFNUCgc4YhOC5zIN88US=> Mn7INlQ3QTd2OU[=
HL-60 NGLMXmZEgXSxdH;4bYMhSXO|YYm= MV20NEDPxE1? M3nXT|Q5KGh? NHuxfllFVVOR MlH6TWM2ODxzMDFOwG0> M1rIPFI1Pjl5NEm2
SMMC-7721 NGO5NWZEgXSxdH;4bYMhSXO|YYm= MY[0NEDPxE1? NHHLeYI1QCCq NGDQVXhFVVOR NXntV29QUUN3ME23MlEh|ryP MUKyOFY6PzR7Nh?=
A-549 MnfsR5l1d3SxeHnjJGF{e2G7 M1LWWVQxKM7:TR?= Mn;POFghcA>? NY[5SW8xTE2VTx?= NHf6c|lKSzVyPEGwJO69VQ>? NHzzdGMzPDZ7N{S5Oi=>
MCF-7 NYW3U|hIS3m2b4TvfIlkKEG|c3H5 M4nmcVQxKM7:TR?= Mn;4OFghcA>? M{fWfGROW09? MWrJR|UxRTdwMzFOwG0> MoPnNlQ3QTd2OU[=
SW-480 MVzDfZRwfG:6aXOgRZN{[Xl? NFraV2U1OCEQvF2= M{n3[lQ5KGh? MmXuSG1UVw>? NXf5fnc6UUN3ME20JO69VQ>? M{\HTVI1Pjl5NEm2
NCI-H929 NWHy[Y1tS3m2b4TvfIlkKEG|c3H5 M13SPFEh|ryP MoiwO|IhcA>? NHfzc3NFVVOR NWDiU3NLUUN3ME2wMlE4KM7:TR?= MV:yOFYzPTB6OB?=
293T M3fldGN6fG:2b4jpZ{BCe3OjeR?= NH7KepoyOCEQvF2= NYH6UGxxPzJiaB?= M{OxOWROW09? NHvufm9KSzVyPEKg{txO MkjLNlQ3OjVyOEi=
293T M4rS[WZ2dmO2aX;uJGF{e2G7 MmC0NVAh|ryP NFrnOHQzPCCq MYTEUXNQ MlziUY9l\XKjdHXsfUBqdmS3Y3XzJIhm[XRvc3jvZ4shKA>? M1Ha[FI1PjJ3MEi4
HeLa NV\LdZpJU2mwYYPlJGF{e2G7 NX;yV3REOTBizszN MVGxJIg> MXjEUXNQ NWDteotSUW6mdXPld{BRSVKSIHPs[YF3[WenIHL5JIlvcGmkaYTpcocheHKxc3Xhd49u\SCjY4Tpeol1gQ>? MUSyOFMzOTh|Mx?=
MDA-MB-231 MkfJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV2xJO69VQ>? NYTHVmtoPzJiaB?= NXv3O|Z2TE2VTx?= NX;BcZZjUUN3ME2wMlE5KM7:TR?= M3ftNVI1OTV|MkC2
MCF-7 M1m2UWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXFNUDPxE1? NVzYUpNTPzJiaB?= M4[5VmROW09? M2[yWmlEPTB;MD6xN{DPxE1? NGnaXHMzPDF3M{KwOi=>
MCF10A NEW0TWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmLqNUDPxE1? MlvKO|IhcA>? NUHiUGltTE2VTx?= MnTpTWM2OD1yLkK5JO69VQ>? NHy5W5ozPDF3M{KwOi=>
HEK-293 MYfLbY5ie2ViQYPzZZk> NE\qU5YzKGGwZDCyNEDPxE1? NUC1PI1TOiCq NVrrRmJqTE2VTx?= M1\5[WlvcGmkaYTzJGNpXC2OIHHjeIl3cXS7IIfpeIghUUN3MDDv[kA6KG6PIB?= NHvBboYzOzV2MEe5NC=>
Calu6 MluzSpVv[3Srb36gRZN{[Xl? NHfT[XQyOCEQvF2= M1H4VlE5KGh? NY\CRlRmTE2VTx?= NIK2R4hUcWewaX\pZ4FvfGy7IHHjZ5VufWyjdHXzJIZz[XSjeHnuJJBz\WO3coPvdi=> MY[yN|UxPjR6Nh?=
IFN-gamma-induced RAW264.7 MofzSpVv[3Srb36gRZN{[Xl? Mo\lSG1UVw>? MWTJcohq[mm2czDubZRzcWNib4jp[IUheHKxZIXjeIlwdiC5aYToJGlEPTBib3[gNE4xPzdizszN MYqyNlI4PzJ5Nx?=
IPC227F MmLNR5l1d3SxeHnjJGF{e2G7 M1nxeVEh|ryP MlfoOFghcA>? NEW3dWVFVVOR MnztTWM2OD1yLkC3O{DPxE1? MmrHNlE6OjR3Mki=
Hepa-1c1c7 MV;GeY5kfGmxbjDBd5NigQ>? NX:wepprOjVizszN NHrRbY83KGh? M3H0SWROW09? M2G3[Wlv[3KnYYPld{BPemZ{IIDyc5RmcW5ibHX2[Yw> M13Yc|IxOzl{NUS0
COS-7 M{PLcWN6fG:2b4jpZ{BCe3OjeR?= NGjTS2YyOCEQvF2= M2rJ[WROW09? NY\TcGpwUUN3MEyxNEDPxE1? M3X4T|E5ODh6MEm3
HuH-7 MkGyR5l1d3SxeHnjJGF{e2G7 MWexNEDPxE1? MUjEUXNQ MkfBTWM2ODxzMDFOwG0> MoP4NVgxQDhyOUe=
OCI-Ly3 MorUSpVv[3Srb36gRZN{[Xl? MoPuNVAh|ryPwrC= MU[0JIg> M1XycWROW09? NV;wOIRrUW6mdXPld{BpfW2jbjDJb4FxeGGEYXzwbIEhe3SjYnnsbZpifGmxbjD3bZRpKEWFNUCgc4YhOSEQvF2= MkDSNVgxOjRzMUO=
A2780 cDDP MV\BdI9xfG:|aYOgRZN{[Xl? NF\Kc|IzPCCq M2fMc2ROW09? M2S5Wmlv\HWlZYOgZZBweHSxc3nzJIJ6KGmwaHnibZRqdmdiUGTFUkBl\We{YXTheIlwdg>? MX6xO|Y5PDBzOB?=
LPS-stimulated RAW264.7 cells MmTLSpVv[3Srb36gRZN{[Xl? NEf5fVhFVVOR MYrJcohq[mm2czDOSk1s[XCyYVKgSG5CKGKrbnTpcoc> M{H1e|E4PDB5Mke3
PC12 NF;rV5ZHfW6ldHnvckBCe3OjeR?= NYrXcZZ[OTByIN88UeKh MoPpNlQhcA>? MVXEUXNQ M3vpSWlvcGmkaYTzJFYuV0iGQT2gZY5lKEh{T{KtbY5lfWOnZDDjfZRwfG:6aXPpeJk> NIP5O3gyPzF3OES1OC=>
PC3 NYfKPGc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUCyNEDPxE1? NVPnO5JzPDhiaB?= MoLBSG1UVw>? NG\LfWtKSzVyPUCuOkDPxE1? Ml\oNVY3QDZ3M{e=
LP-1 NUHZfYZjSXCxcITvd4l{KEG|c3H5 NVLk[IxVOzByIH7N M3fnS|I1KGh? NYLXeoNlTE2VTx?= NWPkR|BDUW6mdXPld{BieG:ydH;zbZMh[nliaX7jdoVie2mwZzDjcIVifmWmIGDBVnAhdGW4ZXygZY5lKHKnZIXjbY5oKE2lbD2xJJBzd3SnaX6gcIV3\Wx? NXv6OXRTOTV7NUi1PFk>
ES6 NFmzTXRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrFTJRKSzVyPUCuNFE{ODZizszN NXfYZldYW0GQR1XS
A101D NGG4SINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwMEOyO|kh|ryP NUe4NYk5W0GQR1XS
OCUB-M MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\UbpVKSzVyPUCuNFM4OzdizszN MX;TRW5ITVJ?
LB2518-MEL NWn5Uo5lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV3JR|UxRTBwMEO3OkDPxE1? MWjTRW5ITVJ?
SH-4 NY[zdoNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRTBwMESzNUDPxE1? M4r1R3NCVkeHUh?=
KNS-42 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX:4RXkzUUN3ME2wMlA1PDRzIN88US=> MoLoV2FPT0WU
DSH1 MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIG0NlRKSzVyPUCuNFUzQDlizszN NIT1VXBUSU6JRWK=
NTERA-S-cl-D1 MoTPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1i5NWlEPTB;MD6wOVc4OiEQvF2= NX3ncYdLW0GQR1XS
D-542MG NFvHOGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPmTWM2OD1yLkC1PVU4KM7:TR?= MlW5V2FPT0WU
KS-1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfk[WVKSzVyPUCuNFY1PThizszN NE[yT2pUSU6JRWK=
BL-41 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfneYdKSzVyPUCuNFY6PDdizszN NGHaNpNUSU6JRWK=
LXF-289 NEG5bpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXLsPGtSUUN3ME2wMlA4ODZ4IN88US=> M4LKVXNCVkeHUh?=
D-247MG M1\mfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUfJR|UxRTBwMEeyNFkh|ryP NX3xeFZLW0GQR1XS
MMAC-SF M2\sdWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7TTWM2OD1yLkC3NlY5KM7:TR?= MUTTRW5ITVJ?
CP66-MEL M17Y[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIXabmhKSzVyPUCuNFc2KM7:TR?= MkjTV2FPT0WU
LB771-HNC MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jSSmlEPTB;MD6wPFA{PiEQvF2= M2f1XXNCVkeHUh?=
no-10 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnkTWM2OD1yLkC4PVA6KM7:TR?= MXvTRW5ITVJ?
A388 NVfzeIVRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXPJR|UxRTBwMEmwOlUh|ryP NXnSTWJwW0GQR1XS
OPM-2 NGjMXIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3r2cWlEPTB;MD6xNFQ4PCEQvF2= NGHuWYZUSU6JRWK=
OVCAR-4 MlztS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUPKS|A5UUN3ME2wMlExQTN6IN88US=> NWT4cGN1W0GQR1XS
HOP-62 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYrxS2NHUUN3ME2wMlExQTR7IN88US=> MWfTRW5ITVJ?
ML-2 NWDE[Y1yT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEXTVFNKSzVyPUCuNVE5ODZizszN MVXTRW5ITVJ?
UACC-257 NHHv[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnG4TWM2OD1yLkGxPVI4KM7:TR?= MkXEV2FPT0WU
NEC8 MlnvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH[3SmlKSzVyPUCuNVE6QTVizszN Mo\0V2FPT0WU
ONS-76 M{PjbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3qTWM2OD1yLkGyPVM2KM7:TR?= MmW4V2FPT0WU
KE-37 NGDuTlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfCOm9KSzVyPUCuNVMzPzhizszN NFW3dVNUSU6JRWK=
HT-144 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{fmNmlEPTB;MD6xN|g6PSEQvF2= M33odHNCVkeHUh?=
LB2241-RCC MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFjBS|JKSzVyPUCuNVQzPDdizszN NGHXdXlUSU6JRWK=
TE-5 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTBwMUSyO|gh|ryP NXnxV|JjW0GQR1XS
KINGS-1 NX;heYdRT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4\jTWlEPTB;MD6xOFc6KM7:TR?= NXPJ[IhQW0GQR1XS
NCI-H69 MnPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVX1R45QUUN3ME2wMlE2OTRzIN88US=> Mn;RV2FPT0WU
CAS-1 Mmn1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mnz3TWM2OD1yLkG1OFgzKM7:TR?= M{P0bnNCVkeHUh?=
D-263MG MknCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTBwMU[wNFYh|ryP M4DwXXNCVkeHUh?=
A253 NGLs[YhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTYTWM2OD1yLkG2NVI5KM7:TR?= NWrBboZHW0GQR1XS
PF-382 NVXYN3ZZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2fRNmlEPTB;MD6xOlcxPiEQvF2= M{XMOXNCVkeHUh?=
CESS NEHmcVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYrJR|UxRTBwMUewOkDPxE1? MY\TRW5ITVJ?
MZ2-MEL MlzQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTETWM2OD1yLkG3OVU6KM7:TR?= NXvGW4xuW0GQR1XS
HEL NYq4[nY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mm\RTWM2OD1yLkG4OVE4KM7:TR?= MWLTRW5ITVJ?
D-392MG NYnYO|g5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlywTWM2OD1yLkG5NVE2KM7:TR?= NI[1fWhUSU6JRWK=
SK-LMS-1 NHLkUJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF\zOW9KSzVyPUCuNVk{ODNizszN MkTBV2FPT0WU
GI-ME-N NWC0[2w{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PxWGlEPTB;MD6xPVMxPiEQvF2= MUXTRW5ITVJ?
LB831-BLC NXOxUG9RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfVTWM2OD1yLkG5N|Qh|ryP NY[xRo01W0GQR1XS
DU-4475 NEe4XlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF64fGtKSzVyPUCuNVk3PThizszN NYjOe4Y1W0GQR1XS
IST-SL1 NX\WeJVNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWDJR|UxRTBwMkCwPVQh|ryP NFWx[XZUSU6JRWK=
GAK NF7iR|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3W5T2lEPTB;MD6yNFU{PCEQvF2= MYnTRW5ITVJ?
EW-1 Ml7QS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXjG[2JOUUN3ME2wMlIyODR5IN88US=> MkXSV2FPT0WU
LAMA-84 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrhTWM2OD1yLkKxPFUyKM7:TR?= NIHmbGtUSU6JRWK=
SK-UT-1 M{G2Vmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXPseWh4UUN3ME2wMlIzODR7IN88US=> M4rQRXNCVkeHUh?=
VA-ES-BJ MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYDJR|UxRTBwMkKyOVch|ryP NHfrU2JUSU6JRWK=
ACN NX7He4tmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVHJR|UxRTBwMkK2N|gh|ryP MkWwV2FPT0WU
SK-PN-DW NEfWOnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX7JR|UxRTBwMkOxPUDPxE1? NGPLO3RUSU6JRWK=
HD-MY-Z M2nnWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLYRoNrUUN3ME2wMlI{OzB|IN88US=> NWPVWm51W0GQR1XS
LB373-MEL-D NWrS[W02T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYLVdGFJUUN3ME2wMlI1OTl6IN88US=> M3TK[3NCVkeHUh?=
COLO-829 NVficVdvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPObGhKSzVyPUCuNlQzPTdizszN M1vlZnNCVkeHUh?=
ES8 NHjWdmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M36w[mlEPTB;MD6yOFc3OyEQvF2= MWrTRW5ITVJ?
RXF393 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3j2c2lEPTB;MD6yOVAyPSEQvF2= NVftZlFGW0GQR1XS
TK10 M{X0e2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYfJR|UxRTBwMkW0N|Uh|ryP NFTWfm1USU6JRWK=
LOUCY M4XTS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFXlS2pKSzVyPUCuNlU1PTZizszN NGfPUVJUSU6JRWK=
MZ7-mel MkLhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVHhboFxUUN3ME2wMlI3Ozd2IN88US=> M13xZ3NCVkeHUh?=
CP67-MEL M4rwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVXJR|UxRTBwMk[3N{DPxE1? NETSW5BUSU6JRWK=
C2BBe1 NG\LUoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nUZWlEPTB;MD6yO|kxPyEQvF2= MnnzV2FPT0WU
K052 Mn\hS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mm[zTWM2OD1yLkK4PVkh|ryP M4jjbnNCVkeHUh?=
MOLT-16 MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmG5TWM2OD1yLkK5OVI1KM7:TR?= MX3TRW5ITVJ?
KNS-81-FD NUDSbm9YT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlmwTWM2OD1yLkOwN|I{KM7:TR?= M4jYRXNCVkeHUh?=
CMK MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rvc2lEPTB;MD6zNVEzKM7:TR?= M2LOR3NCVkeHUh?=
LAN-6 NWTJeW1RT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NI\HN|JKSzVyPUCuN|E{KM7:TR?= NF;GbFZUSU6JRWK=
KLE NYfjb3dST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGHwVJpKSzVyPUCuN|E{ODZizszN M2PG[HNCVkeHUh?=
NCCIT NX\RSmR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2TQbmlEPTB;MD6zNVc5OyEQvF2= NF[0PIVUSU6JRWK=
HH NVLDN|E1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV\nV5BjUUN3ME2wMlMzQDl5IN88US=> M3f2TnNCVkeHUh?=
TE-8 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MV\JR|UxRTBwM{SyO|kh|ryP NGT5fndUSU6JRWK=
GDM-1 NVzvVJJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4jxb2lEPTB;MD6zOVExPCEQvF2= MkjjV2FPT0WU
NCI-H747 NVXm[mY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml\XTWM2OD1yLkO3NVA{KM7:TR?= NYiyfnJjW0GQR1XS
NCI-H1092 M1;wVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWfJR|UxRTBwM{i4OFQh|ryP MVzTRW5ITVJ?
8-MG-BA MmjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVfJR|UxRTBwM{m4N|ch|ryP NHHMVFFUSU6JRWK=
NB17 MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTBwNEK5O{DPxE1? NUDmR29xW0GQR1XS
LC4-1 M3PyUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUfhVHFKUUN3ME2wMlQ{PjB5IN88US=> Mn61V2FPT0WU
TE-1 M4DoOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\OXoVKSzVyPUCuOFUyOTlizszN NVnVeVNmW0GQR1XS
KALS-1 MknnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIP0UHlKSzVyPUCuOFY2QDRizszN M2T2SnNCVkeHUh?=
CCRF-CEM MkjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nTO2lEPTB;MD60O|Y4PCEQvF2= NUP2UIdRW0GQR1XS
OS-RC-2 Mk\KS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPZXlRKSzVyPUCuOFc6PzJizszN NVfOe45zW0GQR1XS
A704 MonMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHPSW5FKSzVyPUCuOFg3QTJizszN MmXzV2FPT0WU
BB49-HNC MkHPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DUcWlEPTB;MD60PVA6PiEQvF2= MmHqV2FPT0WU
EVSA-T MkToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3q0V2lEPTB;MD60PVkyOSEQvF2= NVf3VWFmW0GQR1XS
Mo-T MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX\JR|UxRTBwNUG3OlIh|ryP Mly0V2FPT0WU
MONO-MAC-6 NELnb3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXSTWM2OD1yLkWzOlEyKM7:TR?= NEXuV2dUSU6JRWK=
BB65-RCC NFnBVW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3zNZWlEPTB;MD61OlgyOSEQvF2= M{TyVXNCVkeHUh?=
NCI-H1882 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1HaTmlEPTB;MD61PVA{PiEQvF2= NFHteGlUSU6JRWK=
TE-9 NUPP[WpbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\wVGlEPTB;MD62NVA{OyEQvF2= NFe5WZZUSU6JRWK=
NCI-H2126 M2r0fmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV3JR|UxRTBwNkK2Olkh|ryP MmrQV2FPT0WU
SF268 M3OzRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTBwNkW2OFEh|ryP MWrTRW5ITVJ?
SW872 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVfJR|UxRTBwNkW3Nlkh|ryP MlHFV2FPT0WU
LS-513 NYXjPJp1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTBwNk[3OVEh|ryP NFLETVVUSU6JRWK=
NCI-H1355 NUjq[pZPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIPBdmRKSzVyPUCuOlg3OTlizszN NWO1TIhxW0GQR1XS
BL-70 MnHDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX7JR|UxRTBwNkmzPFgh|ryP NGHaTZdUSU6JRWK=
NCI-SNU-5 NIf6[oZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\QfGlEPTB;MD62PVU1PSEQvF2= MUDTRW5ITVJ?
SNU-C2B NEHtSnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlqyTWM2OD1yLkewO|M6KM7:TR?= NUTEfYh1W0GQR1XS
GB-1 Mnm1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoTZTWM2OD1yLkeyNVI1KM7:TR?= NGLGSJlUSU6JRWK=
CTB-1 MmfFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF\Ub3pKSzVyPUCuO|c6PTVizszN NV\RenB[W0GQR1XS
Becker NUH3dXlYT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXnH[JpQUUN3ME2wMlc6PjJzIN88US=> M1HTS3NCVkeHUh?=
KM12 M4HScGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWnJR|UxRTBwOEW0OlYh|ryP NWrkSHBIW0GQR1XS
ES7 MkLHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlvUTWM2OD1yLki5OlUh|ryP NGjjeY1USU6JRWK=
COLO-684 M{WxTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkDZTWM2OD1yLkmwOlU5KM7:TR?= MmHDV2FPT0WU
HCC2998 NUPTZ2VFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3O1WWlEPTB;MD65N|g2PCEQvF2= MXLTRW5ITVJ?
TE-10 NGq0UG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknjTWM2OD1yLkm2OFMh|ryP MWnTRW5ITVJ?
SF126 M4LoWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYTu[oVQUUN3ME2wMlk5QTdzIN88US=> MVLTRW5ITVJ?
EKVX M1;Wemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmDlTWM2OD1zLkCzOFQzKM7:TR?= NHXFSolUSU6JRWK=
KARPAS-45 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{nvdGlEPTB;MT6wOFAyPiEQvF2= MnHnV2FPT0WU
KGN NUO2d4hoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYHJR|UxRTFwMEWwOFUh|ryP MUHTRW5ITVJ?
ES1 NGrOTYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfKN3VKSzVyPUGuNFc6OjFizszN MkLHV2FPT0WU
L-540 MkTwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PKSGlEPTB;MT6xNVg{QSEQvF2= MlnEV2FPT0WU
KURAMOCHI MorVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4jZTGlEPTB;MT6xNlM4PCEQvF2= NYPZSm9PW0GQR1XS
LU-65 M1n6PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVvCN25EUUN3ME2xMlEzPzV|IN88US=> NYDKT2dtW0GQR1XS
MFH-ino NEDiSYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkPHTWM2OD1zLkG3OVAyKM7:TR?= NELN[2dUSU6JRWK=
NCI-H23 M{TMdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoGyTWM2OD1zLkKwOFEh|ryP M1X6RnNCVkeHUh?=
IA-LM MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVHJR|UxRTFwMkSxNVYh|ryP Mkj5V2FPT0WU
PSN1 MnrSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWnidVJCUUN3ME2xMlI4ODF4IN88US=> NVnYV5R7W0GQR1XS
NCI-H719 MlzUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn7ETWM2OD1zLkK3OFEyKM7:TR?= M2HqdnNCVkeHUh?=
SW684 Ml:yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2nje2lEPTB;MT6yPFY2QSEQvF2= NHHU[GFUSU6JRWK=
HCE-4 NH3FSnVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXrJR|UxRTFwM{CyNlEh|ryP MlXSV2FPT0WU
EW-16 NUjxNGxzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUXJR|UxRTFwM{GzOFch|ryP NUPpdJpSW0GQR1XS
NCI-H128 NUHGOHJIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDSTWM2OD1zLkO1PFE1KM7:TR?= NG\jWWNUSU6JRWK=
HC-1 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1W1fGlEPTB;MT6zPFE4KM7:TR?= M3TpcXNCVkeHUh?=
IST-MES1 NGTJTXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml7NTWM2OD1zLkSwNlA5KM7:TR?= Mof4V2FPT0WU
Raji MoC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVzJR|UxRTFwNEG4OUDPxE1? NIHSdYlUSU6JRWK=
DMS-114 M1y5VGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWTJR|UxRTFwNES1N|kh|ryP M3q5c3NCVkeHUh?=
GI-1 NHTEcpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYfmSpNjUUN3ME2xMlQ4OTNzIN88US=> NHLCeXVUSU6JRWK=
NCI-H2081 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWLq[ZBNUUN3ME2xMlU2OTl4IN88US=> NXXjOFlLW0GQR1XS
LC-1F NV[0[otrT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3vRdmlEPTB;MT61OVE6QCEQvF2= M2j4XnNCVkeHUh?=
NCI-H2227 M4K2[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYi1bXY5UUN3ME2xMlYyPTZzIN88US=> M2O1RXNCVkeHUh?=
D-502MG NYfFZYdpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NE\nW5VKSzVyPUGuOlczOTFizszN Mof1V2FPT0WU
NCI-H2141 NWLQc41pT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGXjR2NKSzVyPUGuOlc{OTdizszN M134OXNCVkeHUh?=
LS-411N M1TEb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGHKNGNKSzVyPUGuOlk5ODdizszN NIrGd4tUSU6JRWK=
SU-DHL-1 M4DTWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfX[IhKSzVyPUGuO|EzQDFizszN NWfxeFBMW0GQR1XS
BB30-HNC M2nlV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn7QTWM2OD1zLkeyOlg2KM7:TR?= NXLZdFhyW0GQR1XS
TE-15 Mkn2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVHJR|UxRTFwOUKzO|Mh|ryP MUHTRW5ITVJ?
JVM-3 NHPlNIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mnz6TWM2OD1zLkmzPVA1KM7:TR?= NGLvWVBUSU6JRWK=
IST-SL2 MkjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrDTWM2OD1{LkCxNlUzKM7:TR?= Mny3V2FPT0WU
EW-18 MoftS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEfJ[Y5KSzVyPUKuNFI{OzdizszN MWjTRW5ITVJ?
DJM-1 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTJwMEK1OVIh|ryP MoPMV2FPT0WU
no-11 NVHNdZdkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Moq5TWM2OD1{LkCzNVA1KM7:TR?= MlX5V2FPT0WU
QIMR-WIL NFHHfm5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M36yRmlEPTB;Mj6xOlc3OiEQvF2= NYKzZ5JTW0GQR1XS
MC-CAR MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYfJR|UxRTJwMkK5OUDPxE1? M4HEOXNCVkeHUh?=
KM-H2 NIDkcFJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlHkTWM2OD1{LkK5NFQ{KM7:TR?= NV:5PZhnW0GQR1XS
ECC12 NFXIbYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4flNmlEPTB;Mj6zO|k1KM7:TR?= NGXWTZFUSU6JRWK=
HCE-T M2jnemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTJwNES4PFMh|ryP NIS4SFBUSU6JRWK=
MFM-223 M2H6Z2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PmbWlEPTB;Mj61NFg4OSEQvF2= NGD5NYpUSU6JRWK=
SW982 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIrKZ2dKSzVyPUKuOVE1QCEQvF2= M3TaOXNCVkeHUh?=
KG-1 M2nm[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlHuTWM2OD1{Lki4O|kyKM7:TR?= NU\qT3RiW0GQR1XS
ES4 M3X1WWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVLJR|UxRTNwME[xNVEh|ryP MX\TRW5ITVJ?
SCC-3 MofhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXHCTIN6UUN3ME2zMlExQDR6IN88US=> M2\XW3NCVkeHUh?=
RH-1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MY\JR|UxRTNwM{i3OFgh|ryP Mmj4V2FPT0WU
NCI-H748 NILNNoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1u1NWlEPTB;Mz60OFI3PiEQvF2= MkHjV2FPT0WU
HCC2218 NEHyd2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mle2TWM2OD1|LkS2PVM4KM7:TR?= MkXqV2FPT0WU
MEG-01 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEK4W3BKSzVyPUOuOVk3QCEQvF2= M4DzRXNCVkeHUh?=
NB12 Mme1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV;JR|UxRTNwNUm4PFgh|ryP Ml\wV2FPT0WU
SNB75 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHi3T|FKSzVyPUOuOlAyODNizszN M1O4RnNCVkeHUh?=
KMS-12-PE MlvOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnfGTWM2OD1|Lk[3O|I{KM7:TR?= M{PMNnNCVkeHUh?=
SKM-1 NFnCVmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NF;Bb45KSzVyPUOuO|E{PzZizszN NX\Dc3JiW0GQR1XS
COLO-320-HSR NUjoZYJGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfiXmxJUUN3ME2zMlc2PjN2IN88US=> MWTTRW5ITVJ?
NKM-1 NXjCemdET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIjxTJRKSzVyPUOuO|c{PzhizszN NH\2V|FUSU6JRWK=
TE-6 NUjVfFJFT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1rZS2lEPTB;Mz65OFU3OSEQvF2= NXrlZlM2W0GQR1XS
D-336MG MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mnm4TWM2OD12LkCxNVY3KM7:TR?= NE\GXXlUSU6JRWK=
NCI-H1650 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rnR2lEPTB;ND6xOVc6PyEQvF2= NUTISVFNW0GQR1XS
ES3 M2myO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHfjWXBKSzVyPUSuN|I5OjRizszN M2LldXNCVkeHUh?=
YT MkfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmGzTWM2OD12LkO1OFI1KM7:TR?= NXj1d5ZQW0GQR1XS
ES5 MoHUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGrseJJKSzVyPUSuOFAzPTVizszN NVjHfXF7W0GQR1XS
LB647-SCLC M4\yWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWXJR|UxRTRwNU[zNFgh|ryP MYrTRW5ITVJ?
HAL-01 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH71R4FKSzVyPUSuOVcxOzRizszN MX7TRW5ITVJ?
LP-1 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYXJR|UxRTRwN{KzO|Eh|ryP MnrmV2FPT0WU
BC-1 NEfIe4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TwUWlEPTB;NT6wNFQ1PyEQvF2= Mn:zV2FPT0WU
EB-3 MlPtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3[0NGlEPTB;NT6wN|A1OSEQvF2= MWPTRW5ITVJ?
GT3TKB MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGezV3pKSzVyPUWuNVc3PjJizszN MkfEV2FPT0WU
NCI-H209 NILXSphIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml36TWM2OD13LkG5N|UzKM7:TR?= MVnTRW5ITVJ?
BT-474 MnXxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3PrVWlEPTB;NT6yN|ExOiEQvF2= MXnTRW5ITVJ?
RKO NHzpXmRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M37C[WlEPTB;NT6yN|QzOiEQvF2= NXnw[ZJIW0GQR1XS
SIMA M3fnTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NH3mcodKSzVyPUWuN|A4PjVizszN MX;TRW5ITVJ?
RL NUjBeYh{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWrJR|UxRTVwM{e1OFEh|ryP MkjOV2FPT0WU
GCIY NED5PYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTVwNEeyN|Yh|ryP MUHTRW5ITVJ?
Calu-6 M2myfmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK2UYVKSzVyPUWuOlIzKM7:TR?= M3XWZnNCVkeHUh?=
ALL-PO NVnL[VdIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXnJR|UxRTVwNkO3PVUh|ryP MUPTRW5ITVJ?
ARH-77 NFG3WpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWXJR|UxRTVwNkewPFch|ryP MlrpV2FPT0WU
A4-Fuk NEPxVYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV\VOFl4UUN3ME22MlA5OTF6IN88US=> M3e5S3NCVkeHUh?=
NCI-H1581 MlXpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MljoTWM2OD14LkKzPFQ6KM7:TR?= Mly0V2FPT0WU
HUTU-80 M1TwbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MormTWM2OD14LkO2PFk4KM7:TR?= MoezV2FPT0WU
TGW NVq1VVQxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVjp[GtVUUN3ME22MlQ2PTl|IN88US=> NW[xUlB{W0GQR1XS
SK-N-FI M3LzTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF;FPVdKSzVyPU[uOFU5PTRizszN Mlv0V2FPT0WU
U-266 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYKzSZN{UUN3ME22MlUyQTJ4IN88US=> M3uzZnNCVkeHUh?=
EM-2 NVXSfoltT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTZwNkewPVkh|ryP NGLVUIFUSU6JRWK=
NMC-G1 NX3CRYNWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHTqUldKSzVyPU[uO|E5QTVizszN NWroe5NoW0GQR1XS
KASUMI-1 M3rEVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4jBUWlEPTB;Nj64OFc5PyEQvF2= MUTTRW5ITVJ?
NALM-6 NGH3RlZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV;UWXR[UUN3ME22Mlg3PzV2IN88US=> NVz5T2toW0GQR1XS
OCI-AML2 NXH3epJWT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXjJR|UxRTdwMECzNlYh|ryP NH;oVVJUSU6JRWK=
SHP-77 M3K5fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NVXXR3NFUUN3ME23MlIzPDNizszN MWfTRW5ITVJ?
NOMO-1 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7BcZFKSzVyPUeuNlQzPTRizszN NWrZe2dOW0GQR1XS
SK-N-DZ M1fGc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHjl[lRKSzVyPUeuO|ExQDlizszN NWXSO21NW0GQR1XS
LB1047-RCC NGTpeXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEW5ZYtKSzVyPUeuO|IzOzFizszN NX\2fGV{W0GQR1XS
MZ1-PC MkDOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{HrTWlEPTB;Nz64OlU2QCEQvF2= M3PQ[XNCVkeHUh?=
NB10 NGG1T5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXzJR|UxRTdwOUm1OVYh|ryP NUm3bG5lW0GQR1XS
RL95-2 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7DV3ZKSzVyPUiuNVA5PDJizszN NYD5Zm5bW0GQR1XS
OMC-1 MlzBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoLaTWM2OD16LkWyNVkyKM7:TR?= NFnmVIhUSU6JRWK=
D-283MED NGm3bGZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XrcGlEPTB;OD65NVcyQSEQvF2= M12ydXNCVkeHUh?=
MC116 MmL4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHf5PWZKSzVyPUiuPVc6PCEQvF2= MkDVV2FPT0WU
SJSA-1 NYXUUWRZT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH7vUmNKSzVyPUmuNFkxQTFizszN Ml;1V2FPT0WU
JiyoyeP-2003 MoH2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXfCXYdXUUN3ME25MlI6OzF5IN88US=> Mkn5V2FPT0WU
IST-MEL1 NV;kcXhET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVfJR|UxRTlwN{SxPVgh|ryP M37HOXNCVkeHUh?=
CTV-1 M1e5cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGTJemtKSzVyPUGwMlA6PzlizszN Mn63V2FPT0WU
NH-12 M3ftZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFH0OVdKSzVyPUGwMlI1OzNizszN Mon6V2FPT0WU
CA46 M1XLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHuxNmdKSzVyPUGwMlM3OSEQvF2= MULTRW5ITVJ?
NCI-SNU-1 MlvLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1O1cmlEPTB;MUCuOFk3QSEQvF2= NGDj[GlUSU6JRWK=
SCLC-21H NHnjNXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYDJR|UxRTFyLk[1PVYh|ryP M37JdHNCVkeHUh?=
EC-GI-10 MmTsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYnzXVdHUUN3ME2xNE44ODNzIN88US=> NWj0XZl5W0GQR1XS
SR NWjTd2JST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MULJR|UxRTFzLkCxPFUh|ryP M{exOnNCVkeHUh?=
NCI-H1648 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUOwRYNTUUN3ME2xNU4xQTZ3IN88US=> Mkm3V2FPT0WU
TGBC1TKB MkjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXzUpJ1UUN3ME2xNU41OTB{IN88US=> NVTGemhuW0GQR1XS
EW-11 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1ywbmlEPTB;MUGuOVE5PiEQvF2= NFXsV2VUSU6JRWK=
SK-MM-2 NIXGSpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHLZ[lVKSzVyPUGxMlgxPjFizszN NXHsNJBbW0GQR1XS
NCI-H524 NGS4TXJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn65TWM2OD1zMT65PFIzKM7:TR?= Ml7DV2FPT0WU
NOS-1 NYjzeWxsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4TMUGlEPTB;MUKuNFM1PSEQvF2= MUHTRW5ITVJ?
AM-38 MnPXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmLKTWM2OD1zMj61OlM{KM7:TR?= M12zfXNCVkeHUh?=
A498 NE[5UFFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXv1elBUUUN3ME2xNk44ODZ7IN88US=> MorGV2FPT0WU
KARPAS-422 NYL0NGFnT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkXBTWM2OD1zMj63OFk3KM7:TR?= NVrnc4FEW0GQR1XS
LU-139 NHPYeHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTF{LkmwNlYh|ryP MV\TRW5ITVJ?
COR-L88 NGTmNIJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1nndmlEPTB;MUKuPVM5OiEQvF2= MkjKV2FPT0WU
K5 NVHVdVhtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M37HVGlEPTB;MUKuPVQ3OiEQvF2= M4frT3NCVkeHUh?=
NB13 M4jLc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1PMU2lEPTB;MUKuPVc5OyEQvF2= MYDTRW5ITVJ?
MRK-nu-1 NFPZc4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrYTWM2OD1zMz6xPVUh|ryP MV3TRW5ITVJ?
MHH-NB-11 NFj0dGJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYruO|FSUUN3ME2xN{4zQTB{IN88US=> NV[zc3hVW0GQR1XS
KU812 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIW0fXNKSzVyPUGzMlYyOjRizszN NXzsd3hJW0GQR1XS
TE-12 MY\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml;KTWM2OD1zMz62PVk1KM7:TR?= MUnTRW5ITVJ?
NCI-N87 NWHRemNzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYDXWVI1UUN3ME2xN{44OzZizszN NIf2[FFUSU6JRWK=
EB2 NHLMPI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIO3dGVKSzVyPUGzMlg2ODVizszN Mmn5V2FPT0WU
DB M{Xw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MneyTWM2OD1zMz65PFg2KM7:TR?= MX3TRW5ITVJ?
697 NGq1NYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVHJR|UxRTF2LkS1NVEh|ryP NGjMbpRUSU6JRWK=
MSTO-211H M{TlWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NInrfW5KSzVyPUG0Mlc1PDhizszN MUDTRW5ITVJ?
JVM-2 NETQdXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1HuOWlEPTB;MUSuO|c{PSEQvF2= Mnm1V2FPT0WU
COLO-824 M2XIfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1GwUWlEPTB;MUSuO|k6PCEQvF2= MVnTRW5ITVJ?
BC-3 MmDBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUj1S3ppUUN3ME2xOU4{QThizszN Mn3yV2FPT0WU
BOKU NVyxNlFkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV\JR|UxRTF3Lkm2NFgh|ryP NXTXZZZ7W0GQR1XS
GOTO MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXfJR|UxRTF4Lkm2NVch|ryP M1P1OHNCVkeHUh?=
HCC2157 NXPlUpRVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{HKWmlEPTB;MUeuOFc2PSEQvF2= NF\lNohUSU6JRWK=
LS-1034 MkTXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4G3OGlEPTB;MUeuOlgyQCEQvF2= NGPQc41USU6JRWK=
CAL-148 MYrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\lTWM2OD1zNz65O|k3KM7:TR?= NEK3SoNUSU6JRWK=
MOLT-4 NUHvO4ZDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlS4TWM2OD1zOD64NlA5KM7:TR?= MXrTRW5ITVJ?
Daudi MmTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33lOWlEPTB;MUiuPVI{OSEQvF2= M2\RZXNCVkeHUh?=
J-RT3-T3-5 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTF7LkSwOlYh|ryP MmOyV2FPT0WU
KMOE-2 NVfRXlFuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojhTWM2OD1zOT62OFgzKM7:TR?= NWTpT4NmW0GQR1XS
HL-60 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWD0TGhsUUN3ME2yNE4yQTZ3IN88US=> M2D6UnNCVkeHUh?=
P31-FUJ NEW2cpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXfJR|UxRTJyLkS3OVMh|ryP NVXocohjW0GQR1XS
IM-9 M3;3OGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjLelVOUUN3ME2yNE43OjJ2IN88US=> NGnIfopUSU6JRWK=
HDLM-2 NUXyVYR5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILvfoFKSzVyPUKwMlg5OjFizszN MnHHV2FPT0WU
NCI-H1304 NGnkcnhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUfvdWZUUUN3ME2yNU4xOzFzIN88US=> NFvkZYVUSU6JRWK=
NCI-H345 Mo\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkfUTWM2OD1{MT6wOlQ{KM7:TR?= NVnPRmhPW0GQR1XS
RPMI-6666 NIm3dXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYjK[HA2UUN3ME2yNU4{PjB{IN88US=> NH;vT3VUSU6JRWK=
GR-ST NHLt[HlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MknyTWM2OD1{MT60NVch|ryP MUPTRW5ITVJ?
CHP-126 NICxdWtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYnJR|UxRTJzLk[xPFEh|ryP M3XpNHNCVkeHUh?=
EHEB MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXPIUmJIUUN3ME2yNU43PzNzIN88US=> M4jKRXNCVkeHUh?=
CPC-N MonDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHH0NnpKSzVyPUK0MlAzODFizszN NWHUUVJRW0GQR1XS
NB1 MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXTJR|UxRTJ2Lk[5N|kh|ryP MkPyV2FPT0WU
LS-123 NVLH[5I1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEHLPVZKSzVyPUK0MlkxOTJizszN NWjxPVdWW0GQR1XS
ST486 M4qxUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYnJXWtrUUN3ME2yOU4yOTF|IN88US=> NX;aRW06W0GQR1XS
NCI-H1963 MoCxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTJ4LkC2NlMh|ryP MVvTRW5ITVJ?
U-87-MG MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mli2TWM2OD1{Nj63OlQ1KM7:TR?= MWnTRW5ITVJ?
COR-L279 NHr2XFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTJ4Lke5NlIh|ryP MVXTRW5ITVJ?
LU-165 MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWXad|JpUUN3ME2yPE4xQDZzIN88US=> NGe2NGlUSU6JRWK=
COLO-800 M1fFcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHS3b3ZKSzVyPUK4MlI6PTZizszN NXe3ZZYxW0GQR1XS
ETK-1 NVO3W3ZoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NETFNnRKSzVyPUK4MlM1PDZizszN MlrBV2FPT0WU
LNCaP-Clone-FGC NHHkS4tIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MW\JR|UxRTJ7LkmyPFEh|ryP MVPTRW5ITVJ?
SIG-M5 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzoN5pKSzVyPUOwMlc6PTJizszN M4nDXXNCVkeHUh?=
NB6 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\TT5NKUUN3ME2zNE46PTB|IN88US=> MXHTRW5ITVJ?
NCI-H2107 NXjRUmFzT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWL6XoE5UUN3ME2zNU4zOzN6IN88US=> MVnTRW5ITVJ?
SNU-C1 NGnCcHJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoTaTWM2OD1|MT6zNVI3KM7:TR?= MVzTRW5ITVJ?
JAR MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH7wfWRKSzVyPUOxMlM4QTlizszN M4WxbnNCVkeHUh?=
L-363 MkTJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIjXUI5KSzVyPUOyMlIyPDRizszN NFq2W3lUSU6JRWK=
EW-24 M3TkXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3;4bmlEPTB;M{KuN|Q4PCEQvF2= NGryW5ZUSU6JRWK=
NB69 MljyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Ml3xTWM2OD1|Mz62OFU1KM7:TR?= NVPpOIpqW0GQR1XS
EW-13 MoX1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGPxUJFKSzVyPUOzMlg6PjlizszN NUC0SJZIW0GQR1XS
Ramos-2G6-4C10 NWH4dZpVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlrETWM2OD1|ND6yPVk{KM7:TR?= M2W1PHNCVkeHUh?=
TE-11 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXXJR|UxRTN2LkS4NlIh|ryP NUHYfWw4W0GQR1XS
L-428 MnnHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWLJR|UxRTN2Lke1N|Yh|ryP NFfDdXJUSU6JRWK=
KP-N-YN NVLRSpc2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTN2LkmwOVch|ryP Mn7GV2FPT0WU
CGTH-W-1 M4fXfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{XHUmlEPTB;M{[uPVA1QCEQvF2= MVHTRW5ITVJ?
K-562 MoH0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYKySJJoUUN3ME2zO{4xQDZ2IN88US=> MVHTRW5ITVJ?
NCI-H1299 NHrPNJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFG2bJlKSzVyPUO4MlE3ODNizszN NXH4ZodLW0GQR1XS
RCC10RGB MoWxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3pdJZKSzVyPUO4MlIxQDNizszN NXWyV3BwW0GQR1XS
NCI-SNU-16 MU\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfpTWM2OD1|OD61OlU{KM7:TR?= MYTTRW5ITVJ?
LC-2-ad NFjHOW9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLBfVd{UUN3ME2zPU41OzN5IN88US=> NG\qPFdUSU6JRWK=
MHH-PREB-1 NIXJPVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVzJR|UxRTN7LkezPFgh|ryP NUnTfHdIW0GQR1XS
NCI-H64 MnPRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTRyLkC5OFgh|ryP M2Lyb3NCVkeHUh?=
LB996-RCC NWfoVVV4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH3ySGVKSzVyPUSwMlg4OTZizszN NGLOcVRUSU6JRWK=
DEL NGK3bXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NEG4V4pKSzVyPUSxMlQ1ODVizszN NHW3fG5USU6JRWK=
MLMA Moj6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYHJR|UxRTRzLke1PVUh|ryP NGH6WJpUSU6JRWK=
SBC-1 M3nwWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYrjbVRqUUN3ME20Nk4yQDB4IN88US=> NGLxZWRUSU6JRWK=
MPP-89 M3LjNmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTR{LkW4O|Uh|ryP NXjvU4lFW0GQR1XS
MV-4-11 M33PeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTR{LkmwOlch|ryP MU\TRW5ITVJ?
EoL-1- NVHhWHNvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{ixeWlEPTB;NESuNVU3QCEQvF2= Mo\wV2FPT0WU
CW-2 M1fZUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{PMOmlEPTB;NESuPFM1OiEQvF2= MkXuV2FPT0WU
HT M3vEUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4fMN2lEPTB;NEWuO|AxPyEQvF2= MWDTRW5ITVJ?
SW954 MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHfEZmZKSzVyPUS3MlQyOjhizszN M37GfHNCVkeHUh?=
A3-KAW M3LvPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NHvmcIRKSzVyPUS5MlgxPjFizszN M2Di[3NCVkeHUh?=
TC-YIK NUjCPZJxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXzzWVdkUUN3ME21NE4xOzZ|IN88US=> NHHRS5ZUSU6JRWK=
SW962 M1nnV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYHBfpdCUUN3ME21OE45OzV5IN88US=> NUG0SnN5W0GQR1XS
KP-N-RT-BM-1 MmHLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MkPQTWM2OD13Nj62OlM5KM7:TR?= NX\mSmRUW0GQR1XS
NCI-H1395 M{DzfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV:1d2h1UUN3ME21PE45OTd{IN88US=> M3:3PXNCVkeHUh?=
RPMI-8402 M2L2Tmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mm\QTWM2OD13OD65OVI3KM7:TR?= NFHBb|NUSU6JRWK=
SCH NFnkbpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmfMTWM2OD14MD65OlM5KM7:TR?= NXnwVoxuW0GQR1XS
NCI-H2196 MlnOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF70V4tKSzVyPU[xMlI{OSEQvF2= NF\vbpNUSU6JRWK=
LOXIMVI MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\qeWlUUUN3ME22NU45OjZ4IN88US=> M1;2XXNCVkeHUh?=
TGBC24TKB M4C3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fSRmlEPTB;NkKuNVQ6OSEQvF2= MnnMV2FPT0WU
SK-MEL-2 NG\nV3ZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1TOe2lEPTB;NkOuPVg6OiEQvF2= MUHTRW5ITVJ?
U-698-M MkjsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkf2TWM2OD14OD61Olg4KM7:TR?= M4TKcXNCVkeHUh?=
NCI-H1522 NE[3XlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4G3XWlEPTB;NkmuNFA1PyEQvF2= M4PO[3NCVkeHUh?=
UACC-812 NGGzNpJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfYTXZTUUN3ME22PU42OjB7IN88US=> MXHTRW5ITVJ?
MHH-CALL-2 NX7kTpd3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MniwTWM2OD15MD6wOkDPxE1? NETC[IpUSU6JRWK=
NB5 NX3VflZ7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTJTWM2OD15MD6zOFY5KM7:TR?= NEHQN2hUSU6JRWK=
KARPAS-299 NW[4RVluT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLpWmtKSzVyPUewMlQ1PDdizszN NFP6VYZUSU6JRWK=
NCI-H1694 NF71XY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUXJR|UxRTdzLkCzNkDPxE1? M1jjS3NCVkeHUh?=
NCI-H82 NF\2WYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGTTXG9KSzVyPUexMlk2ODdizszN NFfzd29USU6JRWK=
SCC-15 NIrqTJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NETsR3lKSzVyPUeyMlM1KM7:TR?= NXy0coQzW0GQR1XS
NCI-H1436 NF3oTJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTd{Lke0OVYh|ryP NWf1cmZpW0GQR1XS
ATN-1 M3mwemdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTd2LkWwOUDPxE1? NGjBPItUSU6JRWK=
RPMI-8866 NEPXTpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVfHNJBzUUN3ME23OE44PTB7IN88US=> NGfsd3hUSU6JRWK=
HCC1599 NFO0VlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYX3TlBFUUN3ME23OE45PzN{IN88US=> NIW5OW5USU6JRWK=
NCI-H1155 NHHVe3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFLlfHhKSzVyPUe0Mlk{PjdizszN NF7UUGZUSU6JRWK=
DOHH-2 M1TnfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mlm3TWM2OD15ND65OVE1KM7:TR?= NVGxXphMW0GQR1XS
SK-NEP-1 MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXS1V3VRUUN3ME23OU4xPzV2IN88US=> NUPH[ppNW0GQR1XS
HCC1187 MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mn;ITWM2OD15Nz62NVIzKM7:TR?= MXPTRW5ITVJ?
NCI-H322M NHLsN4dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M361UmlEPTB;N{iuN|cxQSEQvF2= NGrXS|BUSU6JRWK=
NCI-H526 M2fFU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MV;JR|UxRTd6LkW4O|ch|ryP M2fTUnNCVkeHUh?=
NCI-H2171 Mk[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXUSIYzUUN3ME23PU41OTN4IN88US=> NULHOm93W0GQR1XS
COLO-668 NHLaZm1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXjJR|UxRThzLkW4PFQh|ryP MWPTRW5ITVJ?
RS4-11 NVPt[W84T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVvJR|UxRTh{LkK1NFUh|ryP NXPvb2k{W0GQR1XS
NCI-H716 M2HwVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4C1O2lEPTB;OEKuPVA4PSEQvF2= M3HVW3NCVkeHUh?=
LU-134-A MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXpZ2JDUUN3ME24N{4yOzVzIN88US=> NIftfIpUSU6JRWK=
RPMI-8226 NXLOSnlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWPJR|UxRTh2LkKxNFch|ryP NW\WSVB{W0GQR1XS
KY821 MUHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVzJR|UxRTlzLk[1OVEh|ryP M2\kRXNCVkeHUh?=
ECC4 NYfJc|R1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXHJR|UxRTl|LkiyOlkh|ryP MojJV2FPT0WU
EW-3 NYXvfHc6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWfYOZNbUUN3ME25OE46ODhzIN88US=> M1TjRXNCVkeHUh?=
NB7 NXL5e4hVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PIV2lEPTB;OUWuO|c5PiEQvF2= NVLQZVlXW0GQR1XS
NCI-H720 MmfQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkm3TWM2OD17OD60NFYyKM7:TR?= NVy3VnVmW0GQR1XS
NCI-H446 NH;IS2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M13WUGlEPTB;OUmuO|U5QCEQvF2= M1m5SHNCVkeHUh?=
NCI-H889 MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnjyTWM2OD1zMESuNlQzKM7:TR?= MnHaV2FPT0WU
EW-22 NFXDZlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoLLTWM2OD1zME[uNVkh|ryP MkTIV2FPT0WU
BV-173 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlnJTWM2OD1zMEiuO|I5KM7:TR?= MWjTRW5ITVJ?
WSU-NHL MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmXUTWM2OD1zMEmuOlcyKM7:TR?= M4DjeXNCVkeHUh?=
MN-60 NYm4dpJjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkL5TWM2OD1zMEmuOlkh|ryP NFXhb25USU6JRWK=
DG-75 M1XmWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NY[2XHFVUUN3ME2xNVMvOzV{IN88US=> NHX1OXJUSU6JRWK=
DMS-79 MoT4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXXFVI5KUUN3ME2xNVcvOzh{IN88US=> M160S3NCVkeHUh?=
SK-MEL-1 M2jpfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MU\JR|UxRTFzOD6wNFkh|ryP MV3TRW5ITVJ?
DMS-153 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYnob4RGUUN3ME2xNlEvPzR3IN88US=> NWr6ZnI6W0GQR1XS
NCI-H510A Mm\LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTKTWM2OD1zMkeuN|Ih|ryP NFH2N2NUSU6JRWK=
BE-13 NX3EPZY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M33RcWlEPTB;MUO0MlA1PCEQvF2= MV;TRW5ITVJ?
KP-N-YS NE\scmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVztOnB4UUN3ME2xN|kvPzN4IN88US=> NYn5WXdjW0GQR1XS
SUP-T1 NVfZOXhDT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVm2NnA5UUN3ME2xOFMvPzB6IN88US=> MorjV2FPT0WU
EW-12 MlTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NV70O3Q1UUN3ME2xOFQvPjl7IN88US=> MnzZV2FPT0WU
NB14 NG\XN2pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWPJR|UxRTF2Nz6wPFIh|ryP NGXVWmZUSU6JRWK=
MDA-MB-134-VI M{HvR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTF2OD6yOlgh|ryP M3PrVHNCVkeHUh?=
NCI-H1770 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\keFZKUUN3ME2xOVYvOjd7IN88US=> NGjDXmJUSU6JRWK=
TUR M1vZZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrYeVdKSzVyPUG2O{45PyEQvF2= NVzpeYVQW0GQR1XS
NCI-H1417 M1S3NWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{X2d2lEPTB;MUiwMlM{OSEQvF2= NYfPXlFVW0GQR1XS
IMR-5 M3zl[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkXlTWM2OD1zOEGuOVcyKM7:TR?= NHHOSGJUSU6JRWK=
NCI-H226 NX;5W3dVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUfJe5p{UUN3ME2xPFgvQDZ4IN88US=> NWDWSmJLW0GQR1XS
NCI-H187 M32zbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3VbotKSzVyPUG5NE4xPjRizszN M1rpfnNCVkeHUh?=
SF539 MknFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzoTWM2OD1zOUKuO|I5KM7:TR?= Mnq0V2FPT0WU
TALL-1 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1\p[mlEPTB;MUm4MlMxPCEQvF2= NEHSd|RUSU6JRWK=
TE-441-T NFfFPJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn:zTWM2OD1zOUmuO|M6KM7:TR?= NEmxN4tUSU6JRWK=
REH M{DMUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIG0WIRKSzVyPUKzOk43OjZizszN NXXNdW5tW0GQR1XS
MS-1 M1HVe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{juNWlEPTB;MkO5MlEzOSEQvF2= NU[0cmEyW0GQR1XS
THP-1 MmD0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWjzd21SUUN3ME2yOlQvPzN6IN88US=> MVPTRW5ITVJ?
NCI-H1838 M3vDUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX7nU|lIUUN3ME2yO|EvPDV4IN88US=> NWT0do9PW0GQR1XS
P30-OHK M1zhR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{TWTmlEPTB;MkizMlg1PyEQvF2= MnjLV2FPT0WU
C8166 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV3oS|lVUUN3ME2zOFUvOzN6IN88US=> M2rEcXNCVkeHUh?=

... Click to View More Cell Line Experimental Data

Assay
Methods Test Index PMID
Western Blot
Bcr-Abl; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

Ac-histone H3; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

Cleaved-caspase3; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

Cleaved-PARP; 

PubMed: 26722260     


(C) K562 cells were treated with SAHA (1 µM or 2 µM), MG-132 (400 nM) or SAHA plus MG-132 (400 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. (D) K562G cells were treated with SAHA (1 µM or 2 µM), MG-132 (200 nM) or SAHA plus MG-132 (200 nM) for 24 h. Western blot analysis was performed, using antibodies against Bcr-Abl, Ac-histone H3, caspase-3 and PARP. β-actin was used as a loading control. Representative blots from three independent experiments are shown.

ASCL1; 

PubMed: 19765735     


MG-132 decreases the levels of ASCL1 and CgA in carcinoid cancer cells. Pulmonary (NCI-H727) (A) carcinoid cancer cells were treated with MG-132 (0 to 4µM) for 48 hours and cell lysates were analyzed by Western blotting for the expression of ASCL1 and CgA. Treatment with MG-132 results in a dose dependent inhibition of the two neuroendocrine tumor markers. Analysis for GAPDH confirmed equal loading.

CgA; 

PubMed: 19765735     


MG-132 decreases the levels of ASCL1 and CgA in carcinoid cancer cells. Pulmonary (NCI-H727) (A) carcinoid cancer cells were treated with MG-132 (0 to 4µM) for 48 hours and cell lysates were analyzed by Western blotting for the expression of ASCL1 and CgA. Treatment with MG-132 results in a dose dependent inhibition of the two neuroendocrine tumor markers. Analysis for GAPDH confirmed equal loading.

Nrf2; 

PubMed: 23604711     


MG-132 stimulates Nrf2 and HO-1 protein expression in HAECs in a time-dependent fashion. Cells were treated with MG-132 (2 μM) for various times (0–24 h), and Nrf2 and HO-1 protein were quantified by scanning densitometry, normalized with respect to β-actin, and expressed relative to those of control cells.

HO-1; 

PubMed: 23604711     


MG-132 stimulates Nrf2 and HO-1 protein expression in HAECs in a time-dependent fashion. Cells were treated with MG-132 (2 μM) for various times (0–24 h), and Nrf2 and HO-1 protein were quantified by scanning densitometry, normalized with respect to β-actin, and expressed relative to those of control cells.

26722260 19765735 23604711
Immunofluorescence
C2GnT-M / NMIIA; 

PubMed: 22525330     


Confocal images of bC2GnT-M and NMIIA in cells treated with DMSO (D) or MG-132 (E).

AGS3 / Vimentin; 

PubMed: 20065032     


COS-7 cells were transfected with wild-type or TPR-modified AGS3 (AGS3-TPR [M1 to E470] or AGS3-GPR [E470 to S650]) in pEGFP-N1. Thirty-six hours after transfection, cells were incubated with MG 132 (10 μM) for 12 h, and then the cells were processed for immunofluorescence microscopy. The images presented are representative of 2 to 10 separate transfections.

Bak; 

PubMed: 20557369     


Proteasome inhibitor induces Bak activation. Cells were treated with either vehicle or MG-132 at 10 µmol/L for 12 hours and were subjected to Bak immunofluorescence study using antiserum specific for the N terminus of Bak. Upon Bak activation, this epitope is no longer masked within the protein and becomes available for antibody binding upon Bak conformational change.

22525330 20065032 20557369
Growth inhibition assay
Apoptosis assay; 

PubMed: 20557369     


LX-2 cells were incubated for 24 hours in the presence of increasing concentrations of MG-132 (0, 2.5, 5, 10 µmol/L) and in the presence of the pan-caspase inhibitor QVD at 5 µmol/L for 24 hours. MG-132 and QVD were prepared in DMSO as a vehicle. All data were expressed as mean ± standard error from three individual experiments. * p < 0.01 (10 µmol/L MG-132 treated cells vs. 10 µmol/L MG-132 plus QVD treated cells)

Cell viability; 

PubMed: 26137056     


The proteasome inhibitor MG-132 significantly decreased the cell viability in EC9706 cells in a dose- and time-dependent manner.

cell proliferation ; 

PubMed: 19765735     


MG-132 significantly inhibits growth of carcinoid tumor cells in vitro. Pulmonary (NCI-H727) and GI (BON) carcinoid tumor cells were treated with MG-132 at the indicated concentrations (0 to 4µM) for up to 6 days and cell viability was measured every 2 days with the MTT assay (P<0.001). The results show that MG-132 leads to the suppression cellular proliferation in NCI-H727 (A) and BON (B) cells. (OD, optical density)

20557369 26137056 19765735
ELISA
IL-8; 

PubMed: 11160671     


ELISA of IL-8 from supernatant of eTat cells. eTat cells were blocked with Hu (2 mM) and released. MG-132 (50 μM) was added at the time of release. The supernatant was collected at 3 h postrelease and analyzed for IL-8 protein using ELISA. The result shown is representative of three independent experiments ± standard deviation. 

IL-1beta; 

PubMed: 22606244     


LPS-primed WT BMDM were incubated in control medium or medium containing 10 ng/ml ricin or 25 µg/ml cycloheximide for 4 h. MG-132 (30 µM) or Bortezimib (0.5 µM) was included as indicated. Secreted IL-1ß was measured by ELISA in triplicate wells.

11160671 22606244
In vivo Administration of MG-132 effectively rescues the expression levels and plasma membrane localization of dystrophin, β-dystroglycan, α-bdystroglycan, and α-sarcoglycan in skeletal muscle fibers from mdx mice, reduces muscle membrane damage, and ameliorates the histopathological signs of muscular dystrophy. [7] MG-132 treatment significantly reduces immobilization-induced skeletal muscle atrophy in mice, by downregulating the muscle-specific ubiquitin ligases atrogin-1/MAFbx and MuRF-1 mRNA. [8]

Protocol

Kinase Assay:

[1]

+ Expand

Measurement of inhibitory activities of MG-132 against 20S proteasome:

The reaction mixture for the 20S proteasome inhibitory assay contains 0.1 M Tris-acetate, pH 7.0, 20S proteasome, MG-132, and 25 μM substrate dissolved in dimethyl sulfoxide in a final volume of 1 mL. After incuba tion at 37 °C for 15 minutes, the reaction is stopped by the addition of 0.1 mL of 10% SDS and 0.9 mL of 0.1M Tris acetate, pH 9.0. The fluorescence of the reaction products is measured. To determine the IC50 against 20S proteasome, various concentrations of MG-132 are included in the assay mixture.
Cell Research:

[3]

+ Expand
  • Cell lines: KIM-2, HC11, and ES
  • Concentrations: Dissolved in DMSO, final concentrations ~25 μM
  • Incubation Time: 24 and 48 hours
  • Method:

    Cells are exposed to various concentrations of MG-132 for 24, and 48 hours. Supernatant and monolayer cells are harvested by centrifugation and fixed in 70% ethanol in PBS for staining with acridine orange. Equal volumes of cells and acridine orange (5 mg/mL in PBS) are mixed on a microscope slide and examined by fluorescence microscopy. For annexin V analysis, cells are harvested by centrifugation and stained with annexin V and propidium iodide. For cell cycle analysis, cells are rehydrated in PBS at room temperature for 10 minutes, followed by staining with propidium iodide (5 mg/mL). All samples are analyzed using a Coulter Epics XL flow cytometer.


    (Only for Reference)
Animal Research:

[7]

+ Expand
  • Animal Models: Male mdx (C57BL/10ScSn DMD mdx) mice
  • Formulation: Dissolved in DMSO, and diluted in PBS
  • Dosages: ~10 μg/kg/day
  • Administration: Injection
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 90 mg/mL (189.22 mM)
Ethanol 25 mg/mL (52.56 mM)
Water Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
4% DMSO+30% PEG 300+20% propylene glycol+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 475.62
Formula

C26H41N3O5

CAS No. 133407-82-6
Storage powder
in solvent
Synonyms N/A

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    I want to know whether it contains EDTA or other chelating agent in this product(S2619)?

  • Answer:

    Our S2619 MG-132 doesn't contain EDTA or other chelating agent.

Proteasome Signaling Pathway Map

Proteasome Inhibitors with Unique Features

Related Proteasome Products

Tags: buy MG-132 | MG-132 supplier | purchase MG-132 | MG-132 cost | MG-132 manufacturer | order MG-132 | MG-132 distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID